Answers are grounded in this paper and cite their sources.
Nirsevimab is recommended to prevent severe respiratory syncytial virus (RSV)-associated illness among American Indian/Alaska Native (AI/AN) children <20 months of age. In a test-negative case-control analysis among 291 AI/AN children hospitalized during the 2023-2024 season, nirsevimab was 86.0% and 87.9% effective among children entering their first and second RSV seasons, respectively.
No takes yet. Share an insight, caveat, or question.
Hammitt et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: